Successful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy

被引:5
作者
Gu, Chengyuan [1 ,2 ,3 ]
Wu, Qian [1 ,2 ,3 ]
Zhang, Jingren [1 ,2 ,3 ]
Kang, Liqing [4 ,5 ]
Yu, Lei [4 ,5 ]
Qiu, Huiying [1 ,2 ,3 ]
Wu, Depei [1 ,2 ,3 ]
Chen, Suning [1 ,2 ,3 ]
Yang, Xiaofei [1 ,2 ,3 ,6 ]
机构
[1] Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Inst Blood & Marrow Transplantat, Suzhou, Peoples R China
[3] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
[4] East China Normal Univ, Sch Chem & Mol Engn, Shanghai, Peoples R China
[5] Shanghai Unicar Therapy Biomed Technol Co Ltd, Shanghai, Peoples R China
[6] oochow Univ, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Affiliated Hosp 1, Suzhou 215000, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
D O I
10.1080/10428194.2022.2148209
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:495 / 498
页数:4
相关论文
共 50 条
  • [21] Screening Analysis of Predictive Markers for Cytokine Release Syndrome Risk in CAR-T Cell Therapy
    Xu, Jiayu
    Zhao, Chengkui
    Wei, Zhenyu
    Xie, Weixin
    Cheng, Qi
    Zhang, Min
    Han, Shuangze
    Kang, Liqing
    Xu, Nan
    Yu, Lei
    Feng, Weixing
    CURRENT BIOINFORMATICS, 2024, : 428 - 442
  • [22] A CASE OF RETINOPATHY AFTER CAR-T THERAPY
    Soravia, A.
    Simeon, V.
    Menchini, F.
    Di Renzo, G.
    Di Bin, F.
    Olivieri, J.
    Battista, M. L.
    Facchin, G.
    Lanzetta, P.
    Fanin, R.
    Patriarca, F.
    HAEMATOLOGICA, 2024, 109 : 117 - 117
  • [23] Multimodality Imaging of Acute Myocarditis in Cytokine Release Syndrome (CRS) Following CAR-T Therapy
    Maheswaran, Janane
    Rafice, Moezedin Javad
    Cordes, Sydney
    Lefebvre, Benedicte
    Chetrit, Michael
    CJC OPEN, 2024, 6 (08) : 973 - 977
  • [24] Pediatric ARDS after Car-T therapy
    Wang, Xinhui
    Xiang, Long
    PEDIATRIC PULMONOLOGY, 2024, 59 (06) : 1775 - 1776
  • [25] Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
    Gauthier, Jordan
    Turtle, Cameron J.
    CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2018, 66 (02) : 50 - 52
  • [26] Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
    Rejeski, Kai
    Perez, Ariel
    Iacoboni, Gloria
    Blumenberg, Viktoria
    Buecklein, Veit L.
    Voelkl, Simon
    Penack, Olaf
    Albanyan, Omar
    Stock, Sophia
    Mueller, Fabian
    Karschnia, Philipp
    Petrera, Agnese
    Reid, Kayla
    Faramand, Rawan
    Davila, Marco L.
    Modi, Karnav
    Dean, Erin A.
    Bachmeier, Christina
    von Bergwelt-Baildon, Michael
    Locke, Frederick L.
    Bethge, Wolfgang
    Bullinger, Lars
    Mackensen, Andreas
    Barba, Pere
    Jain, Michael D.
    Subklewe, Marion
    SCIENCE ADVANCES, 2023, 9 (38)
  • [27] Severe cases of local cytokine release syndrome (CRS); craniocervical edema soon after chimeric antigen T-cell (CAR-T) therapy
    Nakamura, Naokazu
    Jo, Tomoyasu
    Arai, Yasuyuki
    Kitawaki, Toshio
    Nishikori, Momoko
    Mizumoto, Chisaki
    Kanda, Junya
    Yamashita, Kouhei
    Nagao, Miki
    Takaori-Kondo, Akifumi
    OXFORD MEDICAL CASE REPORTS, 2025, 2025 (01):
  • [28] Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy
    Juluri, Krishna R.
    Hirayama, Alexandre V.
    Mullane, Erin
    Cleary, Nancy
    Wu, Qian Vicky
    Maloney, David G.
    Turtle, Cameron J.
    Bar, Merav
    Gauthier, Jordan
    BLOOD, 2019, 134
  • [29] RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function
    Zhu, Xiuxiu
    Li, Wuling
    Gao, Jiadong
    Shen, Junjie
    Xu, Yanmin
    Zhang, Chengcheng
    Qian, Cheng
    MEDICAL ONCOLOGY, 2023, 40 (03)
  • [30] RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function
    Xiuxiu Zhu
    Wuling Li
    Jiadong Gao
    Junjie Shen
    Yanmin Xu
    Chengcheng Zhang
    Cheng Qian
    Medical Oncology, 40